Humulin R

Humulin R is a prescription insulin human injection solution that contains the active ingredient insulin human. It is supplied as a clear, sterile solution for subcutaneous, intramuscular, or intravenous administration. The product is manufactured for the European market and is classified as a rapid‑acting insulin in the antidiabetic drug class. Humulin R provides a short‑duration glucose‑lowering effect to help manage blood sugar levels in diabetes as part of daily therapy.

Humulin R is indicated for the management of hyperglycemia in patients with diabetes mellitus.

- Type 1 diabetes mellitus (adults and children) - Type 2 diabetes mellitus (when diet, exercise, and oral agents are insufficient) - Use as a mealtime (prandial) insulin to control post‑prandial glucose spikes - Supplemental insulin in insulin pump therapy or basal‑bolus regimens - Hospitalized patients requiring rapid glucose control via intravenous infusion

Adverse reactions to Humulin R may vary in frequency and severity. Reported events are grouped below.

Common: - Mild hypoglycemia (low blood glucose) - Injection site redness, swelling, or itching - Lipodystrophy (localized fat loss or accumulation) - Transient nausea or abdominal discomfort

Serious: - Severe hypoglycemia with loss of consciousness or seizures - Allergic reactions such as urticaria, angioedema, or anaphylaxis - Acute metabolic acidosis (rare)

Clinicians should consider several precautions when prescribing Humulin R to ensure safe and effective use.

- Adjust dose during periods of illness, stress, or changes in physical activity. - Monitor blood glucose closely when initiating therapy or modifying the regimen. - Use lower initial doses in elderly patients or those with renal or hepatic impairment. - Avoid use in patients with known hypersensitivity to human insulin or any excipients. - Counsel patients on recognizing and treating hypoglycemia promptly. - Consider pregnancy status; insulin requirements may change during gestation.

Humulin R can interact with other medicines, affecting glucose control or increasing the risk of adverse events.

Avoid: - Concurrent use of other rapid‑acting insulins or insulin analogues without dose adjustment. - Beta‑blockers that may mask hypoglycemia symptoms.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk. - Corticosteroids, which may raise blood glucose and require dose changes. - Diuretics, especially loop diuretics, that can alter electrolyte balance and insulin sensitivity. - Alcohol consumption, which can cause delayed hypoglycemia.